The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...

Medtronic is the originator of continuous deep brain stimulation (cDBS), which has been available for decades as a proven ...

Medtronic’s BrainSense aDBS is a therapy intended to improve the quality of life for individuals living with Parkinson’s ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Medtronic (NYSE: MDT) announced today that it received CE mark approval for its BrainSense adaptive deep brain stimulation ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson's Disease (PD).